Efficiency and Safety of Stem Cell Mobilization Following GDP Salvage in Patients With Relapsed or Refractory Lymphoma

Hematological Oncology - United Kingdom
doi 10.1002/hon.112_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma

American Journal of Hematology
Hematology
2019English

Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Outcome of Patients With Relapsed and Refractory Peripheral T Cell Lymphoma Intended for Stem Cell Transplant

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Outcomes of Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory HIV-associated Lymphoma

Bone Marrow Transplantation
TransplantationHematology
2016English

Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

P2-167Gemcitabine, Carboplatin, and Dexamethasone as Salvage Chemotherapy for Outpatients With Relapsed or Refractory Lymphoma

Annals of Oncology
MedicineOncologyHematology
2018English

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

Copanlisib Treatment of Patients With Relapsed or Refractory Marginal Zone Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Annals of Hematology
MedicineHematology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy